Vaxcyte Inc. (NASDAQ:PCVX) is one of the best US stocks to buy under $50. On January 23, Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte Inc. (NASDAQ:PCVX), keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026, with an adult BLA filing planned for 2027. Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations It also noted pro ...

We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the top performers last week. Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema. On Friday alone, the stock jumped to its highest price of $26.95 before giving up all gains to end the session down by ...

Company Performance - IperionX Limited (NASDAQ:IPX) experienced a significant share price increase of 28.4% week-on-week, nearing its all-time high [1] - The stock reached a peak price of $60.35, just $0.55 below its all-time high of $60.90 recorded on October 15 [2] New Deal and Financial Impact - IperionX secured a deal with the US Army valued at $300,000 for the supply of 700 lightweight titanium components for heavy ground combat systems, with potential for significant increases upon successful delivery [3] - The replacement of steel components with titanium is projected to reduce the weight of combat systems by 40 to 45%, enhancing performance metrics such as acceleration, agility, operational range, and survivability [4] Strategic Importance - IperionX is recognized as the only domestic US producer of commercial-scale primary titanium metal, a material deemed strategic and critical by the US Government [5] - The deal aligns with US government priorities to reshore and secure critical materials supply chains, reduce dependence on foreign titanium sources, and expand domestic manufacturing capacity using recycled feedstocks [5]

Group 1 - United Parcel Service, Inc. (UPS) is recognized in the Dividend Contenders List, indicating its strong dividend performance [1] - Evercore ISI raised its price target for UPS to $113 from $94, maintaining an In Line rating, citing a mixed macro backdrop affecting revenue expectations while emphasizing cost initiatives for EPS growth [2] - UPS's fourth-quarter earnings are anticipated to remain stable, reflecting the company's focus on cost management [2] Group 2 - UPS completed the acquisition of Andlauer Healthcare Group (AHG) for approximately C$2.2 billion (USD $1.6 billion), enhancing its healthcare logistics capabilities [2][3] - The acquisition aims to improve UPS's cold chain network, shorten transit times, and enhance quality assurance for healthcare customers [3] - UPS provides integrated logistics and transportation services across more than 200 countries and territories, highlighting its global operational reach [3]

Group 1: Ebola Vaccine Initiative - Merck & Co., Inc. and CEPI are launching a $30 million program to create an updated version of Merck's Ebola vaccine to make it cheaper and easier to distribute in low- and middle-income countries [2] - The partnership will focus on improving the manufacturing process of Merck's WHO-prequalified Ebola vaccine, Ervebo, which is currently complex and expensive to produce at scale [3] - Planned upgrades are expected to increase yield, extend shelf life, and allow Ervebo to be stored in standard refrigerators for several months, enhancing distribution capabilities [4] Group 2: Revenue Growth Outlook - Merck has raised its revenue forecast for new growth drivers to $70 billion by the mid-2030s, driven by the launch of additional drugs [6] - The company now expects cardiometabolic and respiratory treatments to generate about $20 billion in sales, an increase from the previous forecast of $15 billion [7] - Infectious disease drugs are projected to contribute roughly $15 billion, significantly up from an earlier estimate of $5 billion [7] Group 3: Company Overview - Merck & Co., Inc. is a global healthcare giant focused on discovering, developing, manufacturing, and marketing prescription medicines, vaccines, biologic therapies, and animal health products [8]

The Charles Schwab Corporation (NYSE:SCHW) ranks among the best financial stocks to buy according to billionaire Israel Englander. On January 12, Citizens boosted its price target for The Charles Schwab Corporation (NYSE:SCHW) to $120 from $110, maintaining a Market Outperform rating on the company’s shares. Citizens stated that its expectations for The Charles Schwab Corporation (NYSE:SCHW) are persistently above the consensus into 2026, with the firm’s forecasts coming in around 6% higher. Jonathan Wei ...

Core Viewpoint - The Procter & Gamble Company (PG) reported mixed second-quarter 2026 results, reflecting challenges in the U.S. consumer sector but demonstrating resilience in its premium product offerings [2][3]. Financial Performance - PG reported a sales growth of 1%, totaling $22.21 billion, slightly below the consensus estimate of $22.28 billion, attributed to weak U.S. consumer spending and the effects of a government shutdown [3]. - Adjusted earnings per share (EPS) were $1.88, exceeding analyst expectations of $1.86, driven by pricing actions and favorable product mix [4]. - Core gross margin declined for the fifth consecutive quarter due to tariff pressures and investments in value-oriented packaging [4]. Market Outlook - The company reiterated its full-year sales and profit guidance, indicating confidence in navigating a challenging macroeconomic environment [5]. - PG's shares increased by 2%, reflecting investor focus on earnings stability and improving international growth despite the slight revenue miss [5]. Company Overview - PG is a global leader in consumer goods, offering a diversified portfolio of branded household, personal care, and health products across various everyday-use segments [6].

Berkshire Hathaway Inc. (NYSE:BRK-B) is included in our list of the best stocks to buy and hold for 20 years. Berkshire Hathaway (BRK-B) Looks to Exit Its 27.5% Stake in Kraft Heinz Pixabay/Public Domain On January 20, 2026, Reuters reported that Berkshire Hathaway Inc. (NYSE:BRK-B) is possibly exiting its 27.5% stake in Kraft Heinz. The company has made investments in the food and beverage stock for the past ten years. However, the investment has recently failed to meet Warren Buffett’s expectations. ...

Core Viewpoint - Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) has shown strong performance, reaching a three-year high due to impressive earnings and a planned share buyback program of 15 billion Swedish krona [1][5]. Financial Performance - The company reported a net income increase of over 7,000 percent, rising to 28.7 billion Swedish krona from 400 million Swedish krona in 2024 [2]. - In the fourth quarter, net profit grew by 76 percent to 8.6 billion Swedish krona from 4.9 billion Swedish krona year-on-year, despite a 5 percent decline in net sales to 69.3 billion Swedish krona from 72.9 billion Swedish krona [4]. - Overall net sales for the full year decreased by 4.5 percent to 236.7 billion Swedish krona from 247.9 billion Swedish krona [3]. Stock Performance - During intra-day trading, Ericsson's stock peaked at $10.53 before closing at $10.43, reflecting an increase of 8.87 percent [2].

Venture Global, Inc. (NYSE:VG) is one of the stocks Jim Cramer shared his take on. Toward the end of the lightning round, a caller asked about the stock, and Cramer replied: Venture Global, no. Venture Global, we do not like. We did a really good piece about it the other day. We just think that they just didn’t deliver, and we don’t think they’re going to deliver at all. Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels Venture Global, Inc. (NYSE:VG) develops and ...